Risk factors
Enovis (ENOV) risk factors
Item 1A of every Enovis Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors37 risks4 new4 dropped4 reworded
2025 goodwill impairment was $501.0 million, versus $645 million in 2024, tied to lower share price and market capitalization.
Filed Feb 26, 2026 - FY2024 10-K risk factors37 risks
Enovis faces heavy regulatory and compliance scrutiny over its medical devices, intellectual property, and data protection practices. International expansion via the Lima Acquisition increases currency, foreign law, and tariff risks. Restructuring, integration, and debt commitments constrain operational and financial flexibility.
Filed Feb 26, 2025